Patent ID: 8252823

Claim:
A method for treating or ameliorating in a mammal a disease or condition that is causally related to the aberrant activity of the Wnt signaling pathway in vivo, wherein the disease or condition is a cancer of the liver, colon, rectum, breast, or skin, which comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound according to formula I: wherein A is A 1 ; A 1 is x is 1, when A is A 1 ; L 1 is S, SO or SO 2; m1 is 1, 2 or 3; n is 1, 2, 3, 4 or 5; each R 1 ,R 2a ,R 2b , R 2c , and R 2d is independently selected from hydrogen, halo, and substituted or unsubstituted C 1 -C 6 alkyl; R 3 is hydroxy, alkoxy, substituted or unsubstituted amino or cycloheteroalkyl; and each R 4 is independently selected from H, alkyl, substituted alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkythio, substituted or unsubstituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted or unsubstituted sulfonyl, substituted or unsubstituted sulfinyl, substituted or unsubstituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, azido, carboxy, substituted or unsubstituted carbamoyl, cyano, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl, substituted or unsubstituted dialkylamino, halo, heteroaryloxy, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroalkyl, hydroxy, nitro, and thiol; or a pharmaceutically acceptable salt, thereof; and stereoisomers, isotopic variants and tautomers thereof.